Vanguard Global Advisers’s Actuate Therapeutics ACTU Stock Holding History
Bought
Maintained
Sold
Other funds holding ACTU
Vanguard Global Advisers's ACTU Position: Q3 2026 in Review
Vanguard Global Advisers held its Actuate Therapeutics (ACTU) position steady in Q3 2026 at 5,102 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.
Vanguard Global Advisers first reported a position in ACTU in Q1 2026 and has held it in 3 quarters since. The position peaked at $14K in Q1 2026. 33 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.
- Vanguard Global Advisers held 5,102 shares of Actuate Therapeutics worth $3.98K as of Q3 2026.
- Vanguard Global Advisers left its Actuate Therapeutics share count unchanged in Q3 2026.
- Actuate Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3614 holding.
- Vanguard Global Advisers first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 3 quarters since.
- Vanguard Global Advisers's Actuate Therapeutics position peaked at $14K in Q1 2026.
- 33 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.
Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.